Real‐world effectiveness of tirzepatide versus semaglutide for weight loss in overweight or obese patients in an ambulatory care setting
Diabetes, Obesity and Metabolism · 2025-06 · 27 (6) · 3523-3525
DOI: 10.1111/dom.16343 ↗Kurz gefasst
Leserbrief in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 21.03.2025. Verfasst von Huong Trinh und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Department of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha, Nebraska, USA. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- College of Pharmacy, Department of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha, Nebraska, USA.
- Community Based Pharmacy Operations, Nebraska Medicine, Omaha, Nebraska, USA.
ORCID-Profile: Anthony Donovan, Carrie McAdam-Marx
Zitieren
APA
Trinh, H., Donovan, A., & McAdam-Marx, C. (2025). Real‐world effectiveness of tirzepatide versus semaglutide for weight loss in overweight or obese patients in an ambulatory care setting. Diabetes, Obesity and Metabolism, 27(6), 3523-3525. https://doi.org/10.1111/dom.16343
Vancouver
Trinh H, Donovan A, McAdam-Marx C. Real‐world effectiveness of tirzepatide versus semaglutide for weight loss in overweight or obese patients in an ambulatory care setting. Diabetes, Obesity and Metabolism. 2025;27(6):3523-3525. doi:10.1111/dom.16343
BibTeX
@article{Trinh2025,
author = {Trinh, Huong and Donovan, Anthony and McAdam-Marx, Carrie},
title = {Real‐world effectiveness of tirzepatide versus semaglutide for weight loss in overweight or obese patients in an ambulatory care setting},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
volume = {27},
number = {6},
pages = {3523--3525},
doi = {10.1111/dom.16343}
}
EUVIMED